Effects of ezetimibe on glucose metabolism in patients with type 2 diabetes: A 12-week, open-label, uncontrolled, pilot study

van Heek, 2000, Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663, Br J Pharmacol., 129, 1748, 10.1038/sj.bjp.0703235 van Heek, 2001, Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function, Br J Pharmacol., 134, 409, 10.1038/sj.bjp.0704260 Altmann, 2004, Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption, Science., 303, 1201, 10.1126/science.1093131 Dujovne, 2002, Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia, Am J Cardiol., 90, 1092, 10.1016/S0002-9149(02)02798-4 Knopp, 2003, Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: A pooled analysis from two controlled phase III clinical studies, Int J Clin Pract., 57, 363, 10.1111/j.1742-1241.2003.tb10508.x Deushi, 2007, Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome, FEBS Lett., 581, 5664, 10.1016/j.febslet.2007.11.023 Masuda, 2009, Ezetimibe improves postprandial hyperlipidaemia in patients with type lib hyperlipidaemia, Eur J Clin Invest., 39, 689, 10.1111/j.1365-2362.2009.02163.x Shimano, 2008, Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target, J Atheroscler Thromb., 15, 116, 10.5551/jat.E560 1997, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care., 20, 1183, 10.2337/diacare.20.7.1183 Nozue, 2010, Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia, J Atheroscler Thromb., 17, 37, 10.5551/jat.1651 Boden, 2004, Lipids and glucose in type 2 diabetes: What is the cause and effect?, Diabetes Care., 27, 2253, 10.2337/diacare.27.9.2253 Bajaj, 2004, Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes, J Clin Endocrinol Metab., 89, 4649, 10.1210/jc.2004-0224 Davis, 2004, Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis, J Biol Chem., 279, 33586, 10.1074/jbc.M405817200 Temel, 2007, Hepatic Niemann-Pick Cl-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe, J Clin Invest., 117, 1968, 10.1172/JCI30060 Browning, 2004, Molecular mediators of hepatic steatosis and liver injury, J Clin Invest., 114, 147, 10.1172/JCI200422422 Rossebø, 2008, Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis, N Engl J Med., 359, 1343, 10.1056/NEJMoa0804602 Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet., 366, 1267, 10.1016/S0140-6736(05)67394-1 Peto, 2008, Analyses of cancer data from three ezetimibe trials, N Engl J Med., 359, 1357, 10.1056/NEJMsa0806603